Stock Price of Johnson & Johnson (JNJ) Increases 1.41%

Johnson & Johnson s in-depth stock price analysis indicates that the stock price has dropped -0.1% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -3.19% . Looking at the past 52 week period, the stock price is up at 13.18% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Johnson & Johnson has a positive value of 6.48 compared to overall market. Johnson & Johnson (NYSE:JNJ) has climbed 1.41% in the past week and advanced 0.56% in the last 4 weeks. The company has outperformed the S&P 500 by 0.59% in the past week but underperformed the index by 1.24% in the last 4 weeks.

Johnson & Johnson (NYSE:JNJ) : On Friday heightened volatility was witnessed in Johnson & Johnson (NYSE:JNJ) which led to swings in the share price. The stock opened for trading at $114.32 and hit $115.99 on the upside , eventually ending the session at $115.24, with a gain of 1.02% or 1.16 points. The heightened volatility saw the trading volume jump to 6,438,536 shares. The 52-week high of the share price is $126.07 and the company has a market cap of $313,514 million. The 52-week low of the share price is at $99.98 .

Johnson & Johnson Last issued its quarterly earnings results on Jan 24, 2017. The company reported $1.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $1.56. The company had revenue of $18106.00 million for the quarter, compared to analysts expectations of $18259.82 million. The companys revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Johnson & Johnson was Downgraded by Wells Fargo to Market Perform on Jan 26, 2017. Johnson & Johnson was Reiterated by RBC Capital Mkts on Jan 25, 2017 to Outperform, Lowers Price Target to $ 128 from a previous price target of $133 .

Company has reported several Insider transactions to the SEC, on Feb 3, 2017, Michael H Ullmann (Exec VP, General Counsel) sold 21,735 shares at 112.88 per share price.On Jul 28, 2016, Dominic J Caruso (Exec VP, Finance; CFO) sold 41,146 shares at 125.01 per share price.On Jul 25, 2016, Ronald A Kapusta (Controller, CAO) sold 2,935 shares at 125.01 per share price.

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and womens health fields, nutritional and over-the-counter pharmaceutical products. The companys Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and womens health products. Johnson & Johnson is based in New Brunswick, New Jersey.


Share this post

Leave a Reply